LENZ Therapeutics (LENZ) Expected to Announce Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is expected to be issuing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($1.10) per share and revenue of $1.7590 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.25). The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $3.09 million. On average, analysts expect LENZ Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Stock Performance

Shares of LENZ stock opened at $9.28 on Tuesday. The firm’s 50-day moving average is $10.65 and its 200-day moving average is $18.15. The stock has a market cap of $290.93 million, a price-to-earnings ratio of -3.30 and a beta of 0.62. LENZ Therapeutics has a 52-week low of $8.25 and a 52-week high of $50.40.

Wall Street Analysts Forecast Growth

LENZ has been the topic of a number of research analyst reports. Weiss Ratings cut shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Citigroup dropped their target price on shares of LENZ Therapeutics from $52.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday, March 26th. Wall Street Zen cut shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. HC Wainwright lowered their price target on shares of LENZ Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Finally, William Blair reissued an “outperform” rating on shares of LENZ Therapeutics in a report on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Quarry LP bought a new position in LENZ Therapeutics in the 3rd quarter valued at about $27,000. Osaic Holdings Inc. raised its holdings in LENZ Therapeutics by 2,146.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after acquiring an additional 1,116 shares during the period. Tower Research Capital LLC TRC raised its holdings in LENZ Therapeutics by 51.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after acquiring an additional 477 shares during the period. State of Wyoming bought a new position in LENZ Therapeutics in the 4th quarter valued at about $30,000. Finally, BNP Paribas Financial Markets raised its holdings in LENZ Therapeutics by 93.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock valued at $57,000 after acquiring an additional 944 shares during the period. 54.32% of the stock is owned by institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.